✦ LIBER ✦

Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma

✍ Scribed by R'kia Dardari; Meriem Khyatti; Hassan Jouhadi; Abdellatif Benider; Hanae Ettayebi; Abdelouhad Kahlain; Aziz Mansouri; Brahim El Gueddari; Abdellah Benslimane

Publisher: John Wiley and Sons
Year: 2001
Tongue: French
Weight: 64 KB
Volume: 92
Category: Article
ISSN: 0020-7136
DOI: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1177>3.0.co;2-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Human leukocyte antigen class II molecul

Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis

✍ Takeji Umemura; Satoru Joshita; Tetsuya Ichijo; Kaname Yoshizawa; Yoshihiko Kats 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

Overlapping human leukocyte antigen clas

Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma : Evidence of systemic immune dysfunction

✍ Melanoma Study Group of the Mayo Clinic Cancer Center ; Esteban Celis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 645 KB

## Abstract ## BACKGROUND. MPS160 (GRAMLGTHTMEVTV) is a glycoprotein 100‐derived melanoma peptide that contains overlapping human leukemic antigen A2‐, DR53‐, and DQw6‐restricted T‐cell epitopes. In preclinical testing, MPS160 demonstrated superior immunization and antitumor activity. In this repo

Natural T-helper immunity against human

Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7–derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii–restricted epitopes

✍ Sjoerd H. van der Burg; Maaike E. Ressing; Kitty M.C. Kwappenberg; Annemieke de 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 157 KB 👁 1 views

A phase I clinical and pharmacologic stu

A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist